During the 2021 American Society of Clinical Oncology Annual Meeting, multiple trials for targeted treatments were presented for soft tissue sarcoma. Dean Frohlich, PhD, and Brian A. Van Tine, MD, PhD, discuss the the results of some of these presentations, including the Spearhead 1 trial.
In a draft guidance for clinical investigators and sponsors, the FDA made recommendations on how to expand eligibility to patients with incurable cancer through clinical trial designs of investigational cancer drugs and biological products.
A prospective analysis demonstrated a trend toward worse prognosis for patients with metastatic breast cancer who were initially HER2 negative and switched to HER2 positive treated with HER2-directed therapies compared with those who were HER2 positive at diagnosis.
In a retrospective analysis of patients with advanced non–small cell lung cancer and EGFR mutations treated with osimertinib, investigators found that body mass index of 25 kg/mq2 or more had a negative impact on survival outcomes.
A phase 2 trial of tislelizumab and another trial of Tumor Treating Fields accompanied by sorafenib are filling unmet needs in advanced hepatocellular carcinoma, although more data are still needed in this space.
The phase 3 KRYSTAL-10 trial continues to look at the combination of adagrasib and cetuximab in patients with previously treated advanced colorectal cancer and a KRAS G12C mutation in their tumor.
Pembrolizumab plus lenvatinib demonstrated antitumor activity and a manageable safety profile in patients with metastatic renal cell carcinoma who have previously received immune checkpoint inhibitor therapy.
As numerous approvals across cancer settings and emerging approaches are explored in clinical research, new findings presented at the 2021 American Society of Clinical Oncology Annual Meeting in June continue to encourage investigators.
A nonrandomized phase 2 trial of ibrutinib plus venetoclax in patients with treatment naïve chronic lymphocytic leukemia showed durable remissions after more than 3 years of follow-up.
Pertuzumab, trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer showed comparable pathologic complete response with docetaxel, carboplatin, trastuzumab, and pertuzumab with less toxicities.
In an update of the ARROW trial, pralsetinib was well tolerated and demonstrated robust and durable anti-tumor activity in heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.
Patients with previously treated non–small cell lung cancer harboring EGFR exon 20 insertion mutations showed promising preliminary anti-tumor activity and an acceptable safety profile across all of the doses tested in a phase 1 trial of CLN-081.
The phase 2 VERSATILE-002 trial of PDS0101 in combination with pembrolizumab for patients with advanced head and neck cancer has expanded to include those who have progressed on prior treatment with checkpoint inhibitors.
Findings from the Trending Now in Cancer Care 2020 report spotlights the impact of the coronavirus 2019 pandemic, a plummet in cancer screenings, health inequities, and more.
A retrospective analysis showed there were more durable survival outcomes with avapritinib versus other tyrosine kinase inhibitors in adult patients with gastrointestinal stromal tumors and a platelet-derived growth factor receptor A D842V mutation
The ovarian cancer treatment landscape, including the use of cytotoxic and targeted therapies, is continuously evolving for patients. Recent trials have evaluated PARP inhibitors, antiangiogenic agents, and other targeted therapies, and investigators are looking at strategies to individualize care for patients with ovarian cancer.
Patients with high-risk, early-stage triple-negative breast cancer in the phase 3 KEYNOTE-522 trial of pembrolizumab plus chemotherapy after surgery demonstrated statistically significant event-free survival.
Roughly 4% of patients with chronic lymphocytic leukemia treated with ibrutinib may experience atrial fibrillation, but their comorbidities, rather than their CLL-related factors, predict risk of treatment-emergent AF.
The eligibility for and responses to genome-targeted oncology agents increased in United States among patients with cancer from 2006 to 2020.
Chimeric antigen receptor T-cell therapy mediates antigen-dependent and -independent antitumor effects, and CAR T-cell activation of host antitumor immunity is critical for productive solid tumor CAR T immunotherapy.
Surgical oncology expertise has been expanded to local communities in North Texas after physicians from Texas Colon & Rectal Specialists, a large colorectal cancer practice in North Texas, have joined Texas Oncology, increasing The US Oncology Network’s reach.
In a preplanned interim analysis of a phase 2 trial, derazantinib demonstrated antitumor efficacy and met the prespecified threshold for the trial to proceed to the next stage as planned for patients with inoperable or advanced intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions, mutations, or amplifications.
After long-term follow-up, olaparib maintenance therapy demonstrated progression-free survival benefit in almost half of the patients with ovarian cancer compared with 21% for those who received placebo, including consistent benefit in high- and low-risk patients.
Data from a post hoc analysis of the PRIMA/ENGOT-OV26/GOG-3012 phase III trial showed the efficacy of niraparib maintenance therapy for patients with ovarian cancer who had interval debulking surgery or visible residual disease.
Bintrafusp alfa monotherapy demonstrated efficacy, durability, and a manageable safety profile in patients with locally advanced or metastatic biliary tract cancer who have progressed or are intolerant to first-line platinum-based chemotherapy in a phase 2 study, but failed to meet the pre-determined threshold for a regulatory filing.
Undergoing colorectal screening can be a challenge for people who don’t have insurance or are underinsured, so the Colon Cancer Prevention Project was created in Kentucky to help establish programs to improve access to screening, including the Kentucky Colon Cancer Screening and Prevention Program.
A rolling submission of the Biologics License Application was initiated for toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma.
A preplanned analysis of the Regorafenib Dose Optimization Study in patients with metastatic colorectal cancer showed using pre-emptive clobetasol to treat hand–foot skin reactions was more effective than treating this adverse event reactively.
Patients with BRCA-mutated high-risk HER2-negative early breast cancer demonstrated a superior invasive disease-free survival when compared with placebo in the phase 3 OlympiA trial.
The VEGF tyrosine kinase inhibitor tivozanib hydrochloride demonstrated a significantly increased quality-adjusted time without symptoms of disease and toxicity as third- or fourth-line therapy in patients with metastatic renal cell carcinoma compared with sorafenib in the phase 3 TIVO-3 trial.